- ASSISTANT PROFESSOR Medicine, Cardiology
Dr. Meerarani received her doctorate degree in biochemistry at the University of Madras in India. Her research work with Dr. B.Hennig at the Molecular and Cell Nutrition Laboratory, University of Kentucky has focused on the role of nutrients on biochemical and molecular mechanism of vascular endothelial cell function, injury and protection during the development of atherosclerotic disease process.
Dr. Meerarani's research at Mount Sinai is focused along with Dr. Juan Badimon and Dr. Pedro Moreno, in studying the macrophage apoptosis and thrombogenicity, with emphasis in the involvement of tissue factor and tissue factor pathway inhibitor in the development of atherothrombosis. More specifically, using in vivo and in vitro (macrophage and endothelial) cell culture models, the activation of intrinsic and extrinsic coagulation pathways linking cardiovascular risk factors (inflammation, diabetes, hyperlipidemia and smoking) in inducing cell death and thrombogenicity are being studied. Immunofluorescence labeling, flow cytometry, gene and protein expression studies and specific ELISA techniques are being used to investigate the mechanisms involved in linking specific apoptotic pathways with thrombogenicity and tissue factor expression and activity. In addition, she is involved in studying the molecular mechanism of endothelial dysfunction of neovessels in plaque progression and rupture in atherosclerosis.
Hennig B, Purushothaman M, Slim R, Toborek M, Daugherty A, Silverstone AE, Robertson LW. Proinflammatory properties of coplanar PCBs: in vitro and in vivo evidence. Toxicol Appl Pharmacol 2002; 181: 174-183.
Purushothaman M, Smart EJ, Toborek M, Boissonneault GA, Hennig B. Cholesterol attenuates linoleic acid-induced endothelial cell activation. Metabolism 2003; 52: 493-500.
Purushothaman M, Reiterer G, Toborek M, Hennig B. Zinc Modulates PPAR Signaling and Activation of Porcine Endothelial Cells. J Nutr 2003; 133: 3058-3064.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Purushothaman did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Hess CSM Building Floor 7th floor
1470 Madison Avenue
New York, NY 10029
Annenberg Building Floor 24th Floor Room 24-270
1468 Madison Avenue
New York, NY 10029